Katie Tryhane
Stock Analyst at Credit Suisse
(2.03)
# 2,780
Out of 4,791 analysts
21
Total ratings
50%
Success rate
2.57%
Average return
Main Sectors:
Stocks Rated by Katie Tryhane
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Initiates: Outperform | $285 | $139.94 | +103.67% | 1 | Aug 25, 2022 | |
| AVTR Avantor | Maintains: Outperform | $47 → $50 | $15.67 | +219.08% | 1 | Sep 10, 2021 | |
| DHR Danaher | Maintains: Outperform | $306 → $370 | $200.36 | +84.67% | 1 | Sep 10, 2021 | |
| SOPH SOPHiA GENETICS | Initiates: Outperform | $22 | $3.03 | +626.07% | 1 | Aug 17, 2021 | |
| IDXX IDEXX Laboratories | Maintains: Outperform | $735 → $770 | $409.18 | +88.18% | 2 | Aug 13, 2021 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Outperform | $44 → $54 | $2.14 | +2,429.27% | 3 | Aug 11, 2021 | |
| FLGT Fulgent Genetics | Maintains: Underperform | $55 → $65 | $17.27 | +276.38% | 2 | Aug 10, 2021 | |
| ZTS Zoetis | Maintains: Outperform | $206 → $230 | $162.62 | +41.43% | 2 | Aug 9, 2021 | |
| NVST Envista Holdings | Maintains: Outperform | $49 → $55 | $16.11 | +241.40% | 2 | May 6, 2021 | |
| LNTH Lantheus Holdings | Maintains: Neutral | $17 → $20 | $95.41 | -79.04% | 1 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $488 → $490 | $476.48 | +2.84% | 2 | Dec 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $432 → $515 | $154.09 | +234.23% | 2 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $230 → $235 | $162.43 | +44.68% | 1 | Oct 22, 2020 |
Charles River Laboratories International
Aug 25, 2022
Initiates: Outperform
Price Target: $285
Current: $139.94
Upside: +103.67%
Avantor
Sep 10, 2021
Maintains: Outperform
Price Target: $47 → $50
Current: $15.67
Upside: +219.08%
Danaher
Sep 10, 2021
Maintains: Outperform
Price Target: $306 → $370
Current: $200.36
Upside: +84.67%
SOPHiA GENETICS
Aug 17, 2021
Initiates: Outperform
Price Target: $22
Current: $3.03
Upside: +626.07%
IDEXX Laboratories
Aug 13, 2021
Maintains: Outperform
Price Target: $735 → $770
Current: $409.18
Upside: +88.18%
Maravai LifeSciences Holdings
Aug 11, 2021
Maintains: Outperform
Price Target: $44 → $54
Current: $2.14
Upside: +2,429.27%
Fulgent Genetics
Aug 10, 2021
Maintains: Underperform
Price Target: $55 → $65
Current: $17.27
Upside: +276.38%
Zoetis
Aug 9, 2021
Maintains: Outperform
Price Target: $206 → $230
Current: $162.62
Upside: +41.43%
Envista Holdings
May 6, 2021
Maintains: Outperform
Price Target: $49 → $55
Current: $16.11
Upside: +241.40%
Lantheus Holdings
May 5, 2021
Maintains: Neutral
Price Target: $17 → $20
Current: $95.41
Upside: -79.04%
Dec 2, 2020
Maintains: Neutral
Price Target: $488 → $490
Current: $476.48
Upside: +2.84%
Nov 24, 2020
Maintains: Outperform
Price Target: $432 → $515
Current: $154.09
Upside: +234.23%
Oct 22, 2020
Maintains: Outperform
Price Target: $230 → $235
Current: $162.43
Upside: +44.68%